Results 21 to 30 of about 122,816 (266)

Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy

Haematologica
Not available.
Wolfgang Bethge, Peter Dreger, German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy e.V. (DAG-HSZT) - German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)   +2 more
doaj   +1 more source

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial

Frontiers in Oncology, 2023
BackgroundRefractory/relapsed acute myeloid leukemia (R/R AML) has unsatisfactory outcomes even after allogeneic hematopoietic stem cell transplantation.
Chengtao Zhang, Da Gao, Xiaohong Wang, Xiuli Sun, Yan Yan, Yan Yang, Jingjing Zhang, Jinsong Yan, Jinsong Yan, Jinsong Yan   +9 more
doaj   +1 more source

Busulfan in Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation, 2009
The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies. Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of ...
Ciurea, Stefan O., Andersson, Borje S.
openaire   +2 more sources

Thymopoiesis in Pre- and Post-Hematopoietic Stem Cell Transplantation

Frontiers in Immunology, 2018
Hematopoietic stem cell transplantation (HSCT) is an important therapeutic option for some hematological diseases. However, patients who undergo HSCT acquire a state of immunodeficiency that causes significant mortality. Reconstitution of thymic function
Luis Klaus A. da Rocha, Samar Freschi de Barros, Francine Bandeira, Alexia Bollini, Lucia Helena de A. Testa, Anderson João Simione, Marina de O. e Souza, Lilian P. Zanetti, Leila Cibele S. de Oliveira, Ana Claúdia F. dos Santos, Mair Pedro de Souza, Vergílio Antônio R. Colturado, Jorge Kalil, Clarisse M. Machado, Luiza Guilherme   +14 more
doaj   +1 more source

EDTA‐induced pseudothrombocytopenia in hematopoietic stem cell donor

Clinical Case Reports, 2023
We herein report a case of peripheral blood stem cell transplantation (PBSCT) involving a donor with EDTA‐induced pseudothrombocytopenia (PTCP). The apheresis product was inspected for 24 h and there was no platelet clumping or thrombocytopenia.
Misato Tsubokura, Minoru Kojima, Saori Nakabayashi, Noriko Takahashi, Sayaka Takeuchi, Yu Aruga, Chiaki Ikeda, Naoki Maezawa, Koji Okazaki, Sanshiro Uchida, Mizuki Watanabe, Jun Aoki, Ayumu Ito, Takashi Tanaka, Yoshihiro Inamoto, Sung‐Won Kim, Hiromichi Matsushita, Takahiro Fukuda   +17 more
doaj   +1 more source

Comparison between different reduced intensity conditioning regimens in AML/MDS patients in a Latin American center of adult stem cell transplantation

Hematology
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for several hematological diseases. Prospective and retrospective studies have associated myeloablative conditioning regimens with increased non-relapse ...
José Salinas, Yorman Flores, Patricio Rojas, Catherine Gutierrez, Marcela Vidal, Verónica Jara, James Campbell, María José García, Vicente Sandoval, Maximiliano Vergara, Mauricio Ocqueteau, Felipe Palacios, Mauricio Sarmiento   +12 more
doaj   +1 more source

Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide

Pharmaceuticals, 2022
Tacrolimus (Tac) is a pivotal immunosuppressant agent used to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloHSCT).
Daniel N. Marco, María Queralt Salas, Gonzalo Gutiérrez-García, Inés Monge, Gisela Riu, Esther Carcelero, Joan Ramón Roma, Noemí Llobet, Jordi Arcarons, María Suárez-Lledó, Nuria Martínez, Alexandra Pedraza, Ariadna Domenech, Laura Rosiñol, Francesc Fernández-Avilés, Álvaro Urbano-Ispízua, Montserrat Rovira, Mercè Brunet, Carmen Martínez   +18 more
doaj   +1 more source

Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective

Frontiers in Oncology
IntroductionIn resource-limited countries, access to advanced therapies like CAR T-cell therapy is often unattainable. Clinical trials face challenges, with pediatric populations frequently excluded or experiencing significant delays. This highlights the
Carla Nolasco Monteiro Breviglieri, Roseane Vasconcelos Gouveia, Roseane Vasconcelos Gouveia, Valéria Cortez Ginani, Valéria Cortez Ginani, Camila Noronha Santos, Milena Reis Santos de Oliveira, Anna Beatriz Willemes Batalha, Gabriella Sayuri de Alencar, Edna Harumi Goto, Juliana Francielle Marques, Marcia Puato Vieira Pupim, Adriana Seber, Adriana Seber   +13 more
doaj   +1 more source

Blinatumomab-induced remission followed by haploidentical transplantation in pediatric relapsed/refractory pre-B ALL: a multicenter study in Mexico

Frontiers in Oncology
BackgroundPrecursor B-cell acute lymphoblastic leukemia (pre-B ALL) is the most common pediatric cancer worldwide, with cure rates exceeding 85% in high-income countries.
Alberto Olaya-Vargas, Alberto Olaya-Vargas, Haydee Salazar-Rosales, Yadira Melchor-Vidal, Martín Pérez-García, Annecy Herver-Olivares, Gerardo López-Hernández, Nideshda Ramírez-Uribe, Nideshda Ramírez-Uribe, Cesar Galván-Díaz, Irlanda Campos-Pérez, Pilar Cubria-Juárez, Angeles Del Campo-Martínez, Norma López-Santiago, Rocio Cárdenas-Cardos, Rocio Cárdenas-Cardos, Cesar Cárdenas-Pérez Gallardo, Ignacio Mora-Magaña, Jaime Shalkow-Klincovstein   +18 more
doaj   +1 more source

Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes

OncoImmunology, 2017
Use of high-dose, post-transplant cyclophosphamide (PTCy) results in low rates of graft-versus-host-disease (GVHD) and favorable immune reconstitution, although with higher rates of relapse and somewhat high rates of graft failure.
Yu Wang, Ying-Jun Chang, Lu Chen, Lan-Ping Xu, Zhi-Lei Bian, Xiao-Hui Zhang, Chen-Hua Yan, Kai-Yan Liu, Xiao-Jun Huang   +8 more
doaj   +1 more source